Can hydroxyzine be co‑administered with naltrexone safely?

Can Hydroxyzine and Naltrexone Be Used Together?

Yes, hydroxyzine and naltrexone can be co-administered safely, but with important caveats regarding CNS depression monitoring and specific clinical contexts where this combination may be particularly relevant.

Key Safety Considerations

The FDA drug label for hydroxyzine explicitly warns about its potentiating action with central nervous system depressants, stating that "when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced" 1. However, naltrexone is an opioid antagonist, not a CNS depressant, which fundamentally distinguishes this interaction from the typical concern.

Critical Evidence on the Combination

The most relevant clinical evidence comes from a 2017 double-blind, placebo-controlled crossover study demonstrating that palonosetron combined with hydroxyzine (100 mg PO) significantly reduced objective opioid withdrawal scores in an experimental model 2. This suggests the combination of an antihistamine like hydroxyzine with opioid-related medications can be clinically beneficial in specific contexts.

Clinical Context Matters

When This Combination Is Appropriate:

For obesity/weight management with comorbid conditions:

• Naltrexone-bupropion ER is FDA-approved for chronic weight management 3, 4, 3
• Hydroxyzine may be used separately for anxiety, urticaria, or sleep disturbances 5, 6
• No contraindication exists for concurrent use in these scenarios

For alcohol use disorder:

• Naltrexone is recommended for maintaining abstinence in alcohol dependence 7
• Hydroxyzine could address comorbid anxiety or sleep issues
• Monitor for additive sedation but no pharmacologic interaction precludes use

Critical Contraindication - Opioid Use:

The combination becomes problematic only when opioids are involved:

• Naltrexone blocks opioid receptors and will precipitate withdrawal in opioid-dependent patients 8
• Hydroxyzine causes respiratory depression that is additive with opioids but NOT reversible by naloxone 9, 10
• If a patient requires opioid analgesia, naltrexone must be discontinued 7-10 days prior 3

Practical Management Algorithm

Step 1: Assess opioid status

• Current opioid use → Do NOT start naltrexone
• Recent opioid use (within 7-10 days) → Delay naltrexone
• No opioid use → Proceed with caution

Step 2: Monitor for CNS effects

• Start hydroxyzine at lower doses (10-25 mg) if combining with naltrexone
• Watch for excessive sedation, dizziness, or confusion
• Elderly patients require particular caution with hydroxyzine dosing 1

Step 3: Consider QT prolongation risk

• Hydroxyzine can prolong QT interval 1
• Obtain baseline ECG if patient has cardiac risk factors
• Avoid other QT-prolonging medications when possible

Step 4: Hepatic monitoring

• Both medications can affect liver function
• Naltrexone has been associated with hepatocellular injury 7
• Obtain baseline liver function tests and monitor periodically 8

Common Pitfalls to Avoid

1. Assuming naltrexone is a CNS depressant - It is an antagonist and does not directly cause sedation
2. Forgetting about procedural opioid needs - Discontinue naltrexone before procedures requiring fentanyl or other opioids 3
3. Overlooking hydroxyzine's respiratory depression - This effect is NOT reversed by naloxone 9, 10
4. Inadequate opioid-free period - Patients must be completely opioid-free for 7-10 days before starting naltrexone 8

Special Populations

Renal impairment:

• Reduce hydroxyzine dose by 50% in moderate-severe renal impairment 5
• Reduce naltrexone-bupropion ER to half dose in moderate-severe renal impairment 3

Hepatic impairment:

• Avoid hydroxyzine in severe liver disease 5
• Limit naltrexone-bupropion ER to 1 tablet daily in moderate-severe hepatic impairment 3

Elderly patients:

• Start hydroxyzine at low doses (10-25 mg) due to increased sensitivity 1
• Monitor closely for confusion and oversedation

Bottom line: The combination is generally safe when used appropriately, with the primary concern being adequate monitoring for additive CNS effects rather than a direct pharmacologic contraindication. The critical exception is any scenario involving opioid medications, where naltrexone is absolutely contraindicated.